A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 443
- Population
- ALL · 50 Years to 80 Years
- Duration
- 2022-03-01 to 2024-09-23
- Intervention
- JL14002 monoclonal antibody(Fixed dosing regimen); Ranibizumab(Fixed dosing regimen); JL14002 monoclonal antibody(PRN); Ranibizumab(PRN)
- Comparator
- Active Comparator Arm 1 (Drug: Ranibizumab→JL14002 monoclonal antibody); Active Comparator Arm 2 (Drug:Ranibizumab)
- Outcomes measured
- Best-Corrected Visual Acuity (BCVA) Change From Baseline (No. of Letters) to Week 12 — Baseline (Day 0), Week 12; Proportion of subjects who gained at least 5,10 and 15 letters and lose 15 letters baseline to week 12,week 24 and week…; Change From Baseline in CRT(central retina thickness) by visit — Baseline (Day 0), Week 12, Week 24, Week 52; Change from baseline in CNV area from baseline to week 12 and week 52 — Baseline (Day 0), Week 12, Week 52; BCVA Change From Baseline by visit — Baseline (Day 0), Week 24, Week 52; Incidence of drug-related ocular and systemic adverse reactions at Week 12, Week 24, and Week 52. — Baseline (Day 0), W…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.